ENALAPRILAT INJECTION USP DIN 02388499
Health Canada record
| Active ingredient(s) | ENALAPRILAT 1.25 MG |
|---|---|
| Dosage form | Solution |
| Route | Intravenous |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | C09AA02 ENALAPRIL |
| Original market date | 10-Sep-2012 |
| Current status date | 22-May-2024 |
| Source | Health Canada DPD |
Establishment licence of the holder
Hikma Canada Limited — licence 3-002579, currently licensed, last inspection rating C (2022-04-26).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ENALAPRILAT
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 01923846 | VASOTEC IV | SANDOZ CANADA INCORPORATED | Solution | ENALAPRILAT 1.25 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 31181 | 2023-07-10 | Abbreviated New Drug Submission (ANDS) | Administrative: Change in Product Ownership |
| 13410 | 2012-06-22 | Abbreviated New Drug Submission (ANDS) |
International API supply for ENALAPRILAT
2 active FDA Drug Master Files.
Request a quote for ENALAPRILAT INJECTION USP